Provectus Biopharmaceuticals, Inc. (PVCT) Earnings Call Transcripts

Provectus Biopharmaceuticals, Inc.'s Latest Earnings Call - June 18, 2026

In the 2026 Annual Stockholder Meeting for Provectus Biopharmaceuticals, management highlighted significant advancements in their drug development pipeline, particularly with PV-10 and its applications in oncology, dermatology, and ophthalmology. The company reported a cash burn rate of approximately $250,000 per month and expressed optimism about securing additional funding to support ongoing clinical trials. Management maintained a cautious yet positive outlook on the potential for PV-10, emphasizing its unique mechanism of action and collaborations with institutions like NIH and St. Jude's. No revenue figures or earnings were disclosed during the meeting, and no changes to guidance were mentioned, leaving investors to focus on the company's strategic direction and upcoming milestones.

Reported metrics

Guidance from management

Management did not provide specific financial guidance or revenue projections but indicated ongoing efforts to secure funding and expand clinical trials, maintaining a focus on strategic growth and partnerships.

What management said

Good afternoon, everyone. Ladies and gentlemen, on behalf of Provectus Biopharmaceuticals, I'd like to extend a very warm welcome to those here in Knoxville as well as those participating online today. Thank you for attending Provectus' 2026 Annual Meeting of Stockholders. I'm Ed Pershing, Chairman of Provectus Board of Directors and its Chief Executive Officer. We'd like to call the meeting to order and to entertain...

Mr. Chairman, my name is Dominic Rodrigues. I'm the Provectus stockholder, and I moved to waive the reading of the notice of the meeting, the affidavit of mailing of the notice, the proxy material and the minutes of last year's annual meeting.

What analysts pressed on

Analysts expressed concerns regarding the company's cash position and the implications of the proposed reverse stock split. There were also questions about the timeline for clinical trials and the potential for future funding, reflecting uncertainty about the company's financial stability and operational execution.

Main topics on the call

• Collaborations with NIH and St. Jude's — Management announced collaborations with the NIH for HCC liver cancer research and with St. Jude's for pediatric oncology, stating, "We are now working with St. Jude's in that field of research." This marks a significant...
• Mechanism of Action Insights — The CEO emphasized the importance of understanding PV-10's mechanism of action, stating, "Without such knowledge, it would be impossible to capture the full value of our drug agents." This focus on scientific rigor is in...
• Funding and Cash Position — Provectus reported a cash burn rate of approximately $250,000 per month and indicated ongoing efforts to raise $20 million to $25 million. The CEO noted, "We've been working on strategy for raising capital. It dates back...
• Clinical Trials and Future Indications — Management discussed plans for new clinical trials, particularly for oral PV-10, with potential indications including pancreatic cancer. The CEO expressed confidence, stating, "We want to get in there, solve that problem...

Read the full Provectus Biopharmaceuticals, Inc. transcript (June 18, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 3 Provectus Biopharmaceuticals, Inc. earnings call transcripts on record, spanning November 14, 2024 to June 18, 2026. Based on this history, Provectus Biopharmaceuticals, Inc. reports annually. The most recent call on file is dated June 18, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

PVCT

Exchange

OTCPK

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

3

First call

November 14, 2024

Most recent

June 18, 2026

Reporting cadence

annually